New drug for chronic hives registered in Hong Kong
Patients suffering from chronic hives can enjoy more treatment options, as a new drug targeting the disease has been approved for registration in Hong Kong under the “1+” mechanism, the government said on Monday. Under the mechanism, new drugs that are supported by local clinical data as well as recognised by local experts can apply to get registered in the city by submitting the approval from…
Patients with chronic hives now have an additional treatment option in Hong Kong, following the approval of a new drug under the city's innovative "1+" mechanism. This streamlined process allows new drugs to be registered in Hong Kong with just one external drug regulatory authority's approval, rather than the previous requirement of two.
The newly registered drug has received approval from a US authority, and the Registration Committee of Hong Kong has deemed it to meet the necessary safety, efficacy, and quality standards. Chronic spontaneous urticaria, a chronic skin condition causing unpredictable itch and hives, can significantly impact an individual's quality of life.
The new drug offers the potential for sustained improvement in symptom control. Since the "1+" mechanism was introduced in 2023, a total of 22 new drugs have received approval for registration in Hong Kong. Over 910 inquiries have been received by the Department of Health from more than 220 pharmaceutical companies, demonstrating strong interest in utilizing this mechanism to bring their products to the Hong Kong market.
Written by urgent.news from RTHK News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- New drug for chronic hives registered in Hong Kong news.rthk.hk
